Tests for Bladder Cancer

 

If a screening test identifies you as being at risk, you may be given one or more of the following tests:

Cystoscopy (also called cystourethroscopy) - An examination in which a scope, a flexible tube, and viewing device is inserted through the urethra to examine the bladder and urinary tract for structural abnormalities or obstructions, such as tumors or stones. Samples of the bladder tissue may be removed through the cystoscope for examination under a microscope. This procedure is called a biopsy.

Intravenous pyelogram (IVP) - A series of x-rays of the kidney, ureters, and bladder with the injection of a contrast dye into the vein. This test is used to detect tumors, abnormalities, kidney stones, or any obstructions, and to assess renal blood flow. It may also be used to rule out other diseases or check for spread (metastasis) of the bladder cancer to other areas of the urinary tract.

Laboratory tests - Tests may be performed on urine to check for blood, chemicals, bacteria, and cells. Urine may be examined with a microscope or grown in a culture to check for infection. Cancerous cells may be detected using the microscope.

Bladder tumor marker studies - Tests may be performed to determine cellular characteristics and markers or substances released by bladder cancer cells into urine.

Monitoring

Whatever treatment you may have for bladder cancer, it is important to have periodic follow-up testing afterwards. Bladder cancer has a high rate of recurrence, so it is important to catch any new cancer as early as possible. Routine surveillance tests include urinary cytology (looking for new cancer cells in urine) and cystoscopy, which is typically performed every 3 months following treatment of early stage cancer.

This content was last modified on May 02, 2007 .
Latest Cancer News
ACS Guidelines for Breast Screening with MRI May Be Excluding Some High-risk Women

January 6, 2009 — The American Cancer Society (ACS) has developed a set of guidelines to recommend which high-risk women need to undergo screening with breast magnetic resonance imaging (MRI); however, these guidelines may unwittingly exclude some women who are at a high risk of carrying the BRCA mutation yet still don’t meet the limitations set by the ACS. The results of this study were published in the journal Cancer.

Colonoscopy Fails to Identify Many Colorectal Cancers

January 6, 2009 — Colonoscopy, a standard screening method for colorectal cancer, misses the majority of cancers on the right side of the colon and about one-third of cancers on the left side of the colon, according to the results of a study published in the Annals of Internal Medicine. The researchers estimated that the screening method may reduce colorectal cancer mortality by 60-70%, rather than 90% as previously estimated.

High-dose Faslodex® Improves Time to Progression Compared with Arimidex® as Initial Therapy in Advanced Breast Cancer

January 6, 2009 — Researchers affiliated with an international trial have reported that high-dose Faslodex® (fulvestrant) significantly improves time to cancer progression compared with Arimidex® (anastrozole) as initial therapy for hormone-positive, advanced breast cancer. These results were recently presented at the 2008 annual San Antonio Breast Cancer Symposium December 10-14, 2008.

Select news items provided by Reuters Health